No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| PLRZPolyrizon Ltd. | 16.19M | 15.54 | 31.08 | -5.21% | ||||
| TOVXTheriva Biologics, Inc. | 7.49M | 0.21 | -0.01 | -388.69% | 0.08 | |||
| CTXRCitius Pharmaceuticals, Inc. | 17.79M | 0.86 | -0.14 | -258.23% | -59.6% | 0.00 | ||
| ACXPAcurx Pharmaceuticals, Inc. | 6.32M | 2.69 | -0.15 | -0.25% | ||||
| ITRMIterum Therapeutics plc | 17.16M | 0.32 | -0.26 | -69.13% | ||||
| ANTXAN2 Therapeutics, Inc. | 34.25M | 1.25 | -0.73 | -56.29% | ||||
| MCRBSeres Therapeutics, Inc. | 137.33M | 15.18 | -0.80 | 15.37% | 12.34% | 6.65 | ||
| PYPDPolyPid Ltd. | 73.03M | 4.39 | -0.89 | -10.39% | 1.25 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 21.77M | 32.1M | 28.27M | 34.51M | 33.22M | 144.93M | 0 | 0 | 0 |
| Revenue Growth % | - | - | 0.47% | -0.12% | 0.22% | -0.04% | 3.36% | -1% | - | - |
| Cost of Goods Sold | 728K | 81.99M | 89.45M | 95.95M | 0 | 90.57M | 0 | 0 | 0 | 3.53M |
| COGS % of Revenue | - | 3.77% | 2.79% | 3.39% | - | 2.73% | - | - | - | - |
| Gross Profit | -728K | -60.22M | -57.35M | -67.69M | 34.51M | -57.35M | 144.93M | 0 | 0 | -3.53M |
| Gross Margin % | - | -2.77% | -1.79% | -2.39% | 1% | -1.73% | 1% | - | - | - |
| Gross Profit Growth % | 0.93% | -81.72% | 0.05% | -0.18% | 1.51% | -2.66% | 3.53% | -1% | - | - |
| Operating Expenses | 54.86M | 114.61M | 123.5M | 128.55M | 106.38M | 30.77M | 209.42M | 179.91M | 195.1M | 117.78M |
| OpEx % of Revenue | - | 5.27% | 3.85% | 4.55% | 3.08% | 0.93% | 1.45% | - | - | - |
| Selling, General & Admin | 16.76M | 32.62M | 34.04M | 32.6M | 24.75M | 30.77M | 69.26M | 70.26M | 77.5M | 53.18M |
| SG&A % of Revenue | - | 1.5% | 1.06% | 1.15% | 0.72% | 0.93% | 0.48% | - | - | - |
| Research & Development | 38.09M | 81.99M | 89.45M | 95.95M | 80.14M | 90.57M | 141.89M | 109.65M | 117.6M | 64.6M |
| R&D % of Revenue | - | 3.77% | 2.79% | 3.39% | 2.32% | 2.73% | 0.98% | - | - | - |
| Other Operating Expenses | 0 | 0 | 425K | 170K | 1.49M | -90.57M | -1.73M | 0 | 0 | 0 |
| Operating Income | -54.86M | -92.84M | -91.39M | -100.28M | -71.88M | -88.13M | -64.49M | -179.91M | -195.1M | -121.31M |
| Operating Margin % | - | -4.27% | -2.85% | -3.55% | -2.08% | -2.65% | -0.45% | - | - | - |
| Operating Income Growth % | -2.64% | -0.69% | 0.02% | -0.1% | 0.28% | -0.23% | 0.27% | -1.79% | -0.08% | 0.38% |
| EBITDA | -54.13M | -88.63M | -84.14M | -92.42M | -64.27M | -79.24M | -58.55M | -173.28M | -188.85M | -115.85M |
| EBITDA Margin % | - | -4.07% | -2.62% | -3.27% | -1.86% | -2.39% | -0.4% | - | - | - |
| EBITDA Growth % | -2.63% | -0.64% | 0.05% | -0.1% | 0.3% | -0.23% | 0.26% | -1.96% | -0.09% | 0.39% |
| D&A (Non-Cash Add-back) | 728K | 4.21M | 7.26M | 7.86M | 7.6M | 8.89M | 5.95M | 6.63M | 6.24M | 5.47M |
| EBIT | -54.86M | -92.84M | -89.38M | -98.94M | -69.78M | -86.2M | -62.67M | -177.56M | -187.66M | -125.77M |
| Net Interest Income | 83K | 1.26M | 1.59M | 1.17M | 531K | -1.98M | -40K | -2.96M | -5.88M | 3.97M |
| Interest Income | 638K | 2.23M | 0 | 0 | 1.03M | 946K | 2.87M | 3.06M | 7.3M | 3.97M |
| Interest Expense | 555K | 969K | 1.59M | 1.17M | 502K | 2.92M | 2.91M | 6.02M | 13.18M | 0 |
| Other Income/Expense | 76K | 1.26M | 2.02M | 1.34M | 1.6M | -997K | -1.08M | -3.67M | 4.97M | -4.46M |
| Pretax Income | -54.78M | -91.58M | -89.38M | -98.94M | -70.28M | -89.13M | -65.58M | -183.58M | -190.13M | -125.77M |
| Pretax Margin % | - | -4.21% | -2.78% | -3.5% | -2.04% | -2.68% | -0.45% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1.36% | 0.6% | -0% |
| Net Income | -54.78M | -91.58M | -89.38M | -98.94M | -70.28M | -89.13M | -65.58M | -250.16M | -113.72M | 136K |
| Net Margin % | - | -4.21% | -2.78% | -3.5% | -2.04% | -2.68% | -0.45% | - | - | - |
| Net Income Growth % | -2.28% | -0.67% | 0.02% | -0.11% | 0.29% | -0.27% | 0.26% | -2.81% | 0.55% | 1% |
| Net Income (Continuing) | -54.78M | -91.58M | -89.38M | -98.94M | -70.28M | -89.13M | -65.58M | -183.58M | -190.13M | -125.77M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -66.58M | 76.41M | 125.91M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -46.60 | -46.00 | -44.19 | -48.57 | -24.81 | -22.34 | -14.30 | -46.29 | -17.77 | -18.86 |
| EPS Growth % | -4.04% | 0.01% | 0.04% | -0.1% | 0.49% | 0.1% | 0.36% | -2.24% | 0.62% | -0.06% |
| EPS (Basic) | -46.60 | -46.00 | -44.19 | -48.57 | -24.81 | -22.34 | -14.30 | -46.29 | -17.77 | -18.86 |
| Diluted Shares Outstanding | 1.18M | 1.99M | 2.02M | 2.04M | 2.83M | 3.99M | 4.59M | 5.4M | 6.4M | 7.77M |
| Basic Shares Outstanding | 1.18M | 1.99M | 2.02M | 2.04M | 2.83M | 3.99M | 4.59M | 5.4M | 6.4M | 7.77M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 207.61M | 198.37M | 155.08M | 92.67M | 100.19M | 268.78M | 303.63M | 194.76M | 175.41M | 38.67M |
| Cash & Short-Term Investments | 205.08M | 193.24M | 149.98M | 85.82M | 94.82M | 253.62M | 290.71M | 181.34M | 127.97M | 30.79M |
| Cash Only | 73.93M | 54.54M | 36.09M | 85.82M | 65.13M | 116.05M | 180M | 163.03M | 127.97M | 30.79M |
| Short-Term Investments | 131.15M | 138.7M | 113.89M | 0 | 29.69M | 137.57M | 110.7M | 18.31M | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 1.78M | 9.39M | 0 | 0 | 0 | 4.75M |
| Days Sales Outstanding | - | - | - | - | 18.88 | 103.15 | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29.65M | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 6.84M | 0 | 0 | 0 | 13.42M | 17.8M | 3.13M |
| Total Non-Current Assets | 9.29M | 74.28M | 34.44M | 27.81M | 32.25M | 74.16M | 51.23M | 154.02M | 183.19M | 101.14M |
| Property, Plant & Equipment | 7.75M | 36.13M | 32.93M | 26.29M | 30.85M | 22.94M | 36.15M | 133.97M | 108.03M | 92.44M |
| Fixed Asset Turnover | - | 0.60x | 0.97x | 1.08x | 1.12x | 1.45x | 4.01x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 36.75M | 1.51M | 1.4M | 0 | 49.83M | 495K | 9.59M | 0 | 0 |
| Other Non-Current Assets | 1.54M | 1.4M | 0 | 113K | 1.4M | 1.4M | 14.59M | 10.46M | 75.16M | 8.7M |
| Total Assets | 216.9M | 272.65M | 189.52M | 120.47M | 132.44M | 342.94M | 354.86M | 348.78M | 358.6M | 139.81M |
| Asset Turnover | - | 0.08x | 0.17x | 0.23x | 0.26x | 0.10x | 0.41x | - | - | - |
| Asset Growth % | 0.85% | 0.26% | -0.3% | -0.36% | 0.1% | 1.59% | 0.03% | -0.02% | 0.03% | -0.61% |
| Total Current Liabilities | 10.92M | 30.46M | 31.63M | 42.04M | 45.99M | 46.41M | 82.26M | 85.6M | 98.66M | 41.22M |
| Accounts Payable | 5.4M | 7.59M | 7.03M | 6.42M | 4.86M | 4.02M | 13.73M | 17.44M | 3.64M | 4.08M |
| Days Payables Outstanding | 2.71K | 33.78 | 28.7 | 24.4 | - | 16.19 | - | - | - | 421.53 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 454K | 0 | 456K | 0 | 0 |
| Deferred Revenue (Current) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 21.1M | 34.77M | 59.19M | 0 |
| Current Ratio | 19.01x | 6.51x | 4.90x | 2.20x | 2.18x | 5.79x | 3.69x | 2.28x | 1.78x | 0.94x |
| Quick Ratio | 19.01x | 6.51x | 4.90x | 2.20x | 2.18x | 5.79x | 3.69x | 2.28x | 1.48x | 0.94x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 586K | 109.56M | 97.2M | 126.48M | 134.77M | 121.78M | 141.09M | 252.41M | 304.8M | 84.8M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 24.65M | 24.64M | 24.64M | 50.59M | 101.54M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 15.68M | 10.56M | 17.96M | 107.94M | 91.65M | 82.97M |
| Deferred Tax Liabilities | 0 | -10.73M | -6.76M | -5.03M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 586K | 12.8M | 12.35M | 9.64M | 502K | 1M | 11.49M | 1.44M | 16.24M | 1.84M |
| Total Liabilities | 11.51M | 140.01M | 128.82M | 168.52M | 180.76M | 168.19M | 223.35M | 338M | 403.46M | 126.03M |
| Total Debt | 0 | 10.73M | 8.99M | 7.25M | 44.78M | 40.77M | 49.21M | 162.59M | 198.78M | 91.64M |
| Net Debt | -73.93M | -43.81M | -27.1M | -78.57M | -20.35M | -75.28M | -130.79M | -440K | 70.82M | 60.85M |
| Debt / Equity | - | 0.08x | 0.15x | - | - | 0.23x | 0.37x | 15.08x | - | 6.65x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -98.84x | -95.81x | -57.48x | -85.57x | -143.18x | -30.14x | -22.16x | -29.89x | -14.81x | - |
| Total Equity | 205.39M | 132.63M | 60.7M | -48.05M | -48.32M | 174.75M | 131.51M | 10.78M | -44.86M | 13.78M |
| Equity Growth % | 8.69% | -0.35% | -0.54% | -1.79% | -0.01% | 4.62% | -0.25% | -0.92% | -5.16% | 1.31% |
| Book Value per Share | 174.56 | 66.57 | 30.01 | -23.58 | -17.06 | 43.80 | 28.68 | 2.00 | -7.01 | 1.77 |
| Total Shareholders' Equity | 205.39M | 132.63M | 60.7M | -48.05M | -48.32M | 174.75M | 131.51M | 10.78M | -44.86M | 13.78M |
| Common Stock | 39K | 40K | 40K | 41K | 70K | 91K | 92K | 125K | 135K | 173K |
| Retained Earnings | -82.61M | -174.19M | -263.57M | -389.37M | -459.65M | -548.78M | -614.35M | -864.51M | -978.24M | -978.1M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 30K | -149K | -146K | -20.3M | 0 | -47K | -60K | -12K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -40.84M | 43.92M | -75.52M | -62.85M | -76.52M | -93.61M | 6.69M | -228.82M | -117.35M | -148.61M |
| Operating CF Margin % | - | 2.02% | -2.35% | -2.22% | -2.22% | -2.82% | 0.05% | - | - | - |
| Operating CF Growth % | -2.94% | 2.08% | -2.72% | 0.17% | -0.22% | -0.22% | 1.07% | -35.21% | 0.49% | -0.27% |
| Net Income | -54.78M | -91.58M | -89.38M | -98.94M | -70.28M | -89.13M | -65.58M | -250.16M | -113.72M | 136K |
| Depreciation & Amortization | 728K | 4.21M | 7.26M | 7.86M | 7.6M | 6.58M | 5.95M | 6.63M | 6.24M | 5.47M |
| Stock-Based Compensation | 9.69M | 16.86M | 17.36M | 16.64M | 8.34M | 8.82M | 20.22M | 25.48M | 34.1M | 20.97M |
| Deferred Taxes | 7K | 0 | 0 | 0 | 103K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 367K | -386K | -213K | -214K | 2.34M | 3.31M | 4.57M | 7.62M | 15M | -109.67M |
| Working Capital Changes | 3.14M | 114.82M | -10.55M | 11.8M | -24.63M | -23.2M | 41.53M | -18.39M | -58.98M | -65.51M |
| Change in Receivables | 0 | 0 | 0 | 0 | -1.78M | -7.6M | 9.39M | 0 | -8.67M | -2.07M |
| Change in Inventory | 0 | 0 | 0 | 0 | -3.86M | -2.87M | 0 | 0 | -29.65M | -33.8M |
| Change in Payables | 2.68M | 3.58M | -856K | -353K | -1.46M | -1.16M | 9.36M | 2.2M | -11.58M | -2.94M |
| Cash from Investing | -137.13M | -65.45M | 56.99M | 112.32M | -30.52M | -158.89M | 64.09M | 82.43M | 10.58M | 142.29M |
| Capital Expenditures | -4.36M | -21.49M | -4.68M | -1.94M | -1M | -591K | -9.57M | -9.82M | -7.97M | -380K |
| CapEx % of Revenue | - | 0.99% | 0.15% | 0.07% | 0.03% | 0.02% | 0.07% | - | - | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -1.4M | 139K | -113K | 114.25M | -29.52M | -19.9M | 0 | 92.25M | 0 | -13.52M |
| Cash from Financing | 137.72M | 2.14M | 83K | 268K | 86.23M | 303.42M | 1.18M | 129.6M | 71.7M | -90.37M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -2.67M | 2.14M | 116K | 404K | 16K | 14.88M | 2.13M | 2.73M | 3.03M | 14M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -45.21M | 22.43M | -80.2M | -64.79M | -77.52M | -94.2M | -2.88M | -238.64M | -125.33M | -148.99M |
| FCF Margin % | - | 1.03% | -2.5% | -2.29% | -2.25% | -2.84% | -0.02% | - | - | - |
| FCF Growth % | -2.98% | 1.5% | -4.58% | 0.19% | -0.2% | -0.22% | 0.97% | -81.92% | 0.47% | -0.19% |
| FCF per Share | -38.42 | 11.26 | -39.65 | -31.80 | -27.37 | -23.61 | -0.63 | -44.16 | -19.58 | -19.17 |
| FCF Conversion (FCF/Net Income) | 0.75x | -0.48x | 0.84x | 0.64x | 1.09x | 1.05x | -0.10x | 0.91x | 1.03x | -1092.71x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 2.45M | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -61.32% | -54.18% | -92.46% | -1563.81% | - | -140.99% | -42.83% | -351.62% | - | 0.99% |
| Return on Invested Capital (ROIC) | - | -63.22% | -111.98% | - | - | -429.2% | -96.56% | -2440.28% | -806.07% | -180.9% |
| Gross Margin | - | -276.68% | -178.68% | -239.46% | 100% | -172.68% | 100% | - | - | - |
| Net Margin | - | -420.74% | -278.44% | -350.03% | -203.68% | -268.33% | -45.25% | - | - | - |
| Debt / Equity | - | 0.08x | 0.15x | - | - | 0.23x | 0.37x | 15.08x | - | 6.65x |
| Interest Coverage | -98.84x | -95.81x | -57.48x | -85.57x | -143.18x | -30.14x | -22.16x | -29.89x | -14.81x | - |
| FCF Conversion | 0.75x | -0.48x | 0.84x | 0.64x | 1.09x | 1.05x | -0.10x | 0.91x | 1.03x | -1092.71x |
| Revenue Growth | - | - | 47.48% | -11.94% | 22.07% | -3.74% | 336.33% | -100% | - | - |
| 2018 | 2019 | |
|---|---|---|
| License And Service | 26.92M | 27.19M |
| License And Service Growth | - | 1.01% |
Seres Therapeutics, Inc. (MCRB) reported $0.4M in revenue for fiscal year 2024.
Seres Therapeutics, Inc. (MCRB) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Seres Therapeutics, Inc. (MCRB) is profitable, generating $5.4M in net income for fiscal year 2024 (1536.8% net margin).
Seres Therapeutics, Inc. (MCRB) has a return on equity (ROE) of 1.0%. This is below average, suggesting room for improvement.
Seres Therapeutics, Inc. (MCRB) had negative free cash flow of $23.4M in fiscal year 2024, likely due to heavy capital investments.